PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
29.77%
Net income growth above 1.5x TRAW's 11.71%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-0.50%
Both reduce yoy D&A, with TRAW at -20.00%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
15.92%
Some yoy growth while TRAW is negative at -223.09%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
0.65%
SBC growth while TRAW is negative at -7.78%. John Neff would see competitor possibly controlling share issuance more tightly.
-31.26%
Both reduce yoy usage, with TRAW at -512.63%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.84%
A yoy AP increase while TRAW is negative at -149.12%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-40.45%
Negative yoy usage while TRAW is 95.48%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-15.92%
Negative yoy while TRAW is 223.09%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
32.67%
Operating cash flow growth above 1.5x TRAW's 0.87%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
100.00%
CapEx growth well above TRAW's 100.00%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above TRAW's 100.00%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-58.30%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.